Sign Out
Mycophenolate mofetil (CellCept) in combination with corticosteroids and either ciclosporin or tacrolimus is indicated for: prophylaxis of acute organ rejection and treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants; prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. (In the treated population, MMF improved survival in the first year after transplantation); prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.
Mycophenolate mofetil (CellCept) is indicated for induction and maintenance therapy of patients with Class III-V lupus nephritis (diagnosed according to International Society of Nephrology/Renal Pathology Society classification).
